

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
30 September 2021 (30.09.2021)



(10) International Publication Number  
**WO 2021/195426 A1**

(51) International Patent Classification:

*A61K 35/30* (2015.01) *A61P 25/16* (2006.01)  
*A61P 25/00* (2006.01) *A61P 25/28* (2006.01)  
*A61P 25/02* (2006.01)

(21) International Application Number:

PCT/US2021/024228

(22) International Filing Date:

25 March 2021 (25.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/994,750 25 March 2020 (25.03.2020) US

(71) Applicant: **SANA BIOTECHNOLOGY, INC.** [US/US];  
188 East Blaine Street, Suite 400, Seattle, WA 98102 (US).

(72) Inventor; and

(71) Applicant: **RAMOS-ZAYAS, Rebeca** [—/US]; 168  
Adams Street Unit 1, Waltham, MA 02453 (US).

(72) Inventor: **SCHREPFER, Sonja**; 1 Tower Place, Suite 500,  
South San Francisco, CA 94080 (US).


(74) Agent: **NG, Jennifer, K.** et al.; Morgan, Lewis & Bockius  
LLP, One Market, Spear Street Tower, San Francisco, CA  
94105 (US).

(81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,  
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,  
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,  
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,  
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every  
kind of regional protection available*): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: **HYPOIMMUNOGENIC NEURAL CELLS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS AND  
CONDITIONS**

Figure 1



(57) Abstract: Disclosed herein are cells including neural cells that evade immune recognition such as microglial response and related methods of their use and generation. In some embodiments, the cells disclosed herein have reduced levels or activities of MHC I and/or MHC II human leukocyte antigens, and in some instances, exogenously express CD47. In some embodiments, the cells are derived from pluripotent stem cells that evade immune recognition by a recipient subject.

[Continued on next page]

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**

- *with international search report (Art. 21(3))*